Clinical trials: Cancer: Solid Tumors
Advanced Solid Tumors
Safety of Recombinant Human IL-21-expressing Oncolytic Vaccinia Virus Injection (hV01) in Advanced Tumors
The goal of this clinical trial is to evaluate the safety, tolerance, pharmacokinetics, and biological properties of recombinant human IL-21-expressing oncolytic vaccinia virus injection (hV01) in patients with advanced solid…
- Trial name
- NCT05914376
- Testing
- Recombinant human IL-21-expressing oncolytic vaccinia virus injection
- Where
- 2 sites in China
- Volunteers
- 24 people
- Sponsor
- Hangzhou Converd Co., Ltd.
TMB-H, Histologically or Cytologically Proven Metastatic or Locally Advanced Solid Tumors
A Study of IMC-001 In Patients With Metastatic Or Locally Advanced TMB-H Solid Tumor
The goal of this clinical trial is to determine the efficacy of IMC-001 in metastatic or locally advanced TMB-H solid tumor patients.
- Trial name
- TMB-H (NCT06365840)
- Testing
- IMC-001
- Where
- 4 sites in South Korea
- Volunteers
- 30 people
- Sponsor
- ImmuneOncia Therapeutics Inc.
Solid Tumors, Lymphoma
Study of Ulevostinag (MK-1454) Alone or in Combination With Pembrolizumab (MK-3475) in Participants With Advanced/Metastatic Solid Tumors or Lymphomas (MK-1454-001)
The purpose of this study is to identify a maximum tolerated dose (MTD) or maximum administered dose (MAD) of ulevostinag alone and of ulevostinag in combination with pembrolizumab in participants with advanced/metastatic solid…
- Trial name
- NCT03010176
- Testing
- Ulevostinag, Pembrolizumab
- Where
- 19 sites in United States, France and 3 more
- Volunteers
- 156 people
- Sponsor
- Merck Sharp & Dohme LLC
Solid Tumor, Adult
Study of FCN-437c in Patients With Advanced Solid Tumors
This research study is studying a drug called FCN-437c as a possible treatment for patients with advanced unresectable/metastatic solid tumors.
- Trial name
- FCN-437c (NCT03951116)
- Testing
- FCN-437
- Where
- 3 sites in United States
- Volunteers
- 22 people
- Sponsor
- Fochon Pharmaceuticals, Ltd.
Malignant Lymphoma of Extranodal and/or Solid Organ Site, Solid Tumor
Safety Study of Camptothecin-20-O-Propionate Hydrate (CZ48)
This is a single-arm, non-randomized feasibility and Phase I trial of 20(S) Camptothecin Propionate administered orally. CZ48 will be administered in successive cohorts of 1 patient per participating site until hints of toxicity…
- Trial name
- NCT02575638
- Testing
- CZ48
- Where
- United States
- Volunteers
- 65 people
- Sponsor
- Cao Pharmaceuticals Inc.
Advanced Solid Tumor
Study of RP-3500, Camonsertib, in Advanced Solid Tumors
The primary purpose of this study is to define the maximum tolerated dose (MTD) and determine a recommended Phase 2 dose (RP2D) and schedule of orally-administered RP-3500 (camonsertib) alone or in combination with talazoparib, a…
- Trial name
- TRESR (NCT04497116)
- Testing
- RP-3500 (camonsertib), Talazoparib, Gemcitabine Injection
- Where
- 13 sites in United States, Canada and 2 more
- Volunteers
- 276 people
- Sponsor
- Repare Therapeutics
Advanced Solid Tumors, Metastatic Triple Negative Breast Cancer
Study of NK012 and Carboplatin in Solid Tumors With Dose Expansion in Triple Negative Breast Cancer
The primary objective is to determine the maximum tolerated dose/recommended phase II dose of the combination regimen of NK012 and carboplatin in patients with advanced solid tumors.
- Trial name
- NCT01238952
- Testing
- NK012 and carboplatin
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- Nippon Kayaku Co., Ltd.
Solid Tumors, Sarcoma
First-in-Human Trial of DS-2243a in Participants With Advanced Solid Tumors
This 2-part study will evaluate safety, tolerability, and clinical efficacy of DS-2243a as a treatment for participants with advanced solid tumors.
- Trial name
- NCT06644755
- Testing
- DS-2243a
- Where
- 7 sites in United States, Belgium and 3 more
- Volunteers
- 150 people
- Sponsor
- Daiichi Sankyo
Advanced Solid Tumor
The Absorption, Metabolism and Excretion of [14C]CM082 in Human
This is a single-center, open-label, single-dose phase I study to investigate the absorption, metabolism and excretion of [14C] CM082 in healthy Chinese male subjects.
- Trial name
- NCT04434326
- Testing
- [14]CM082 suspension
- Where
- China
- Volunteers
- 4 people, healthy volunteers welcome
- Sponsor
- AnewPharma
Melanoma, Non Small Cell Lung Cancer
A Clinical Study of LM103 Injection in the Treatment of Advanced Solid Tumors
This is a single-arm, open-label, exploratory study to evaluate safety and efficacy of LM103 Injection in patients with advanced solid tumors.
- Conditions
- Melanoma, Non Small Cell Lung Cancer, Cervical Carcinoma
- Trial name
- NCT05366478
- Testing
- Autologous tumor infiltrating lymphocytes (TILs)
- Where
- China
- Volunteers
- 15 people
- Sponsor
- Suzhou BlueHorse Therapeutics Co., Ltd.
Advanced Solid Tumors
SNV4818 in Participants With Advanced Solid Tumors
This study is testing a new medicine, SNV4818, for people with advanced cancers. The researchers want to find out if SNV4818 is safe, well-tolerated, and effective in treating solid tumors.
- Trial name
- NCT06736704
- Testing
- SNV4818, Fulvestrant, Palbociclib
- Where
- 12 sites in United States, Australia and 1 more
- Volunteers
- 320 people
- Sponsor
- Pikavation Therapeutics, Inc.
Neoplasm Metastasis, Non-Small Cell Lung Cancer
Beamion LUNG-1: A Study to Test Different Doses of Zongertinib in People With Different Types of Advanced Cancer (Solid Tumours With Changes in the HER2 Gene)
The study has 2 parts. The first part is open to adults with different types of advanced cancer (solid tumours with changes in the HER2 gene) for whom previous treatment was not successful.
- Trial name
- NCT04886804
- Testing
- zongertinib
- Where
- 85 sites in United States, Australia and 16 more
- Volunteers
- 554 people
- Sponsor
- Boehringer Ingelheim
Locally Advanced or Metastatic Solid Tumors
A Combination Therapy Study of MK-2206 and AZD6244 in Participants With Advanced Solid Tumors (MK-2206-010)
This study will investigate the safety and tolerability of combination therapy with MK-2206 and AZD6244 (selumetinib) and determine the maximum tolerated dose (MTD) and recommended Phase 2 dose (RPTD) for this drug combination in…
- Trial name
- NCT01021748
- Testing
- MK-2206, AZD6244
- Volunteers
- 63 people
- Sponsor
- Merck Sharp & Dohme LLC
Advanced Solid Tumor
Clinical Trial of TQB2618 Injection Combined With TQB2450 Injection in Patients With Advanced Solid Tumors
This project is a phase Ib clinical trial study evaluating the efficacy and safety of TQB2618 injection combined with TQB2450 injection in patients with advanced solid tumors, the trial plan to enroll 127 subjects, the trial…
- Trial name
- NCT05645315
- Testing
- TQB2618 injection and TQB2450 injection
- Where
- 5 sites in China
- Volunteers
- 127 people
- Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Advanced Solid Tumors, Lymphoma
Safety and Pharmacologic Study of VTX-2337 in Patients With Advanced Cancer
This is a multi-center, Phase I study of a new investigational drug, VTX-2337, that may stimulate the immune system to help fight cancer.
- Trial name
- NCT00688415
- Testing
- VTX-2337
- Where
- 2 sites in United States
- Volunteers
- 33 people
- Sponsor
- Celgene
Advanced Solid Tumor
A Study of Single Drug TJ011133 and Toripalimab Combine Treatment for Advanced Solid Tumor
This study is a phase I/II study of single drug TJ011133 and Toripalimab combine treatment forAdvanced solid tumor. This study include two stages. First stage is dose escalation and second stage is dose extension.
- Trial name
- NCT05148533
- Testing
- TJ1133 Injection
- Where
- 22 sites in China
- Volunteers
- 7 people
- Sponsor
- TJ Biopharma Co., Ltd.
Solid Tumors
An Open-Label Dose-Escalation Study to Evaluate XmAb24306 as a Single Agent and in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Solid Tumors
This study will evaluate the safety, tolerability, pharmacokinetics, and activity of XmAb24306 alone or in combination with a checkpoint inhibitor treatment in participants with locally advanced or metastatic solid tumors.
- Trial name
- NCT04250155
- Testing
- XmAb24306, Atezolizumab
- Where
- 25 sites in United States, Australia and 7 more
- Volunteers
- 195 people
- Sponsor
- Genentech, Inc.
Solid Tumor, Lung Cancer
A Study to Evaluate the Efficacy and Safety of Anti-PD-1 Antibody AK105 in Patients With Selected Advanced Solid Tumors
This is a multi-center, multi-cohort, open-label, phase Ib/II study to evaluate the efficacy, safety, PK characteristics, immunogenicity and potential biomarkers of AK105 monotherapy in the patients with selected advanced solid…
- Conditions
- Solid Tumor, Lung Cancer, HCC
- Trial name
- NCT04172506
- Testing
- AK105
- Where
- China
- Volunteers
- 65 people
- Sponsor
- Akeso
Cancer, Solid Tumors
Dose Escalation Study of Safety and Tolerability of AT-406 in Patients With Advanced Solid Tumors and Lymphomas
The purpose of this study is to determine the safety profile and the maximum dose of Debio 1143 (AT-406) that can be given to humans.
- Conditions
- Cancer, Solid Tumors, Lymphoma, Malignancy
- Trial name
- NCT01078649
- Testing
- Debio 1143 (AT-406)
- Where
- 3 sites in United States
- Volunteers
- 51 people
- Sponsor
- Debiopharm International SA
Advanced Malignant Solid Tumor
First-in-human Safety and Tolerability of MP0317 in Patients With Relapsed/Refractory Advanced Solid Tumors
This study is investigating a new experimental therapy, MP0317, a DARPin® drug candidate targeting fibroblast activation protein (FAP) and CD40.
- Trial name
- NCT05098405
- Testing
- MP0317, a tri-specific fibroblast activation protein (FAP) x CD40 DARPin® drug candidate (q3w regimen), MP0317, a tri-specific fibroblast activation protein (FAP) x CD40 DARPin® drug candidate (q1w regimen)
- Where
- 4 sites in France, Netherlands
- Volunteers
- 46 people
- Sponsor
- Molecular Partners AG
The first 5,000 results can be paged through. Add a filter or change the sort order to reach the rest.